Navigation Links
AbbVie Demonstrates 96 percent SVR(12) in its Phase III Study of Treatment-Experienced Patients with Genotype 1 Hepatitis C
Date:12/10/2013

i>
  • ABT-333
  • 12 weeksPEARL-III

    GT1b, treatment-naive

    (400 a)

  • ABT-450/r +ABT-267
  • ABT-333
  • Ribavirin
  • 12 weeks

  • ABT-450/r +ABT-267
  • ABT-333
  • Placebo
  • 12 weeksPEARL-IV

    GT1a, treatment-naive

    (300 a)

  • ABT-450/r +ABT-267
  • ABT-333
  • Ribavirin
  • 12 weeks

  • ABT-450/r +ABT-267
  • ABT-333
  • Placebo
  • 12 weeksTURQUOISE-II

    GT1, treatment-naive and treatment-experienced (with compensated cirrhosis)

    (380 a)

  • ABT-450/r +ABT-267
  • ABT-333
  • Ribavirin
  • 12 weeks

  • ABT-450/r +ABT-267
  • ABT-333
  • Ribavirin
  • 24 weeksa projected study population

    b ABT-450/ritonavir

    c ABT-267 is co-formulated with ABT-450/r, administered as two pills once daily

    The 3D regimen consists of boosted protease inhibitor ABT-450/ritonavir, NS5A inhibitor ABT-267, and non-nucleoside polymerase inhibitor ABT-333. The combination of three different mechanisms of action interrupts the HCV replication process with the goal of optimizing SVR rates across different patient populations. In May of 2013, AbbVie's investigational 3D regimen with and without ribavirin for HCV GT1 was designated as a Breakthrough Therapy by the U.S. Food and Drug Administration (FDA).

    ABT-450 was discovered during the ongoing collaboration between AbbVie and Enanta Pharmaceuticals (NASDAQ: ENTA) for HCV protease inhibitors and regimens that include protease inhibitors. ABT-450 is being developed by AbbVie for use in combination with AbbVie's other investigational medicines for the treatment of HCV.

    Safety Information for Ribavirin and RitonavirRibavirin and ritonavir are not approved for the investigational use discussed above, and no conclusions can or should be drawn regarding the safety or ef
    '/>"/>

    SOURCE AbbVie Inc.
    Copyright©2012 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6

    Related medicine technology :

    1. AbbVie Named to S&P 500 Dividend Aristocrat Index
    2. AbbVie Issues Inaugural Full-Year Outlook for 2013
    3. AbbVie to Present at Barclays Global Health Care Conference
    4. Receptos Licenses Anti-Interleukin-13 Antibody from AbbVie for Phase 2 Development in Orphan Disease
    5. AbbVie to Host First-Quarter Earnings Conference Call
    6. AbbVie Reports First-Quarter 2013 Financial Results
    7. AbbVie CF Scholarship Application Now Available for Exceptional Undergraduate and Graduate Students with Cystic Fibrosis
    8. AbbVies Investigational HCV Regimen Receives Breakthrough Therapy Designation from the U.S. Food and Drug Administration
    9. AbbVie to Present at Bank of America Merrill Lynch 2013 Health Care Conference
    10. AbbVie and Alvine to Collaborate on Investigational Oral Therapy for Celiac Disease
    11. AbbVie to Present Data on Investigational Anti-Cancer Compounds at American Society of Clinical Oncology Annual Meeting
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:12/24/2014)... Mexico , Dec. 24, 2014  Novastem, ... of its first patient in its study for ... the American Stroke Association, ischemic strokes account for ... to enroll qualified patients in the study, entitled ... Administration of Allogeneic Mesenchymal Stem Cells and Intrathecal ...
    (Date:12/24/2014)... PRINCETON, N.J. , Dec. 24, 2014 /PRNewswire/ ... Company), a late-stage biopharmaceutical company developing products that ... inflammation, oncology and biodefense, announced today that on ... registered public offering. The Company raised ... offering and intends to use the net proceeds ...
    (Date:12/24/2014)... , December 24, 2014 ... at an average rate of 8.1%. The US has ... knee and spine surgeries are the common orthopedic procedures ... have a lower penetration. Increased number of product recalls ... Non-metallic orthopedic devices have gained popularity in the industry ...
    Breaking Medicine Technology:Novastem Treats First Patient Using Stemedica's Mesenchymal and Neural Stem Cell Combination Therapy for Ischemic Stroke 2Novastem Treats First Patient Using Stemedica's Mesenchymal and Neural Stem Cell Combination Therapy for Ischemic Stroke 3Novastem Treats First Patient Using Stemedica's Mesenchymal and Neural Stem Cell Combination Therapy for Ischemic Stroke 4Soligenix Announces Closing of Public Offering of Units 2Soligenix Announces Closing of Public Offering of Units 3Use of Composites in Orthopedic Industry to Reach $596 Million by 2020 2Use of Composites in Orthopedic Industry to Reach $596 Million by 2020 3
    ... AURORA, Ohio , June 25 ... medical repair parts for hospital equipment, has been honored ... by Inside Business Magazine.  Now in its 13th year, ... industry,s greatest accomplishments by honoring local companies for their ...
    ... Soligenix, Inc. (OTC Bulletin Board: SNGX) (Soligenix ... the publication of an article in the June ... protection from mucosal and systemic ricin intoxication by intradermal ... ricin toxin. The article was authored by the Company,s ...
    Cached Medicine Technology:PartsSource Wins 2010 Manny Award for Workplace Environment 2Soligenix Announces Publication of Positive Data Describing Protection from Mucosal and Systemic Ricin Intoxication by Intradermal RiVax™ Administration 2Soligenix Announces Publication of Positive Data Describing Protection from Mucosal and Systemic Ricin Intoxication by Intradermal RiVax™ Administration 3Soligenix Announces Publication of Positive Data Describing Protection from Mucosal and Systemic Ricin Intoxication by Intradermal RiVax™ Administration 4Soligenix Announces Publication of Positive Data Describing Protection from Mucosal and Systemic Ricin Intoxication by Intradermal RiVax™ Administration 5Soligenix Announces Publication of Positive Data Describing Protection from Mucosal and Systemic Ricin Intoxication by Intradermal RiVax™ Administration 6Soligenix Announces Publication of Positive Data Describing Protection from Mucosal and Systemic Ricin Intoxication by Intradermal RiVax™ Administration 7
    (Date:12/25/2014)... 26, 2014 “Every three months the trends ... A-line sweetheart evening dress will be one of the hottest ... of Yunx.co.uk says. Today, the company releases 26 A-line sweetheart ... to 80% off. , “We are trying our best ... with our latest designs. Along with affordable prices, we provide ...
    (Date:12/25/2014)... December 25, 2014 Recently, BellasDress ... on all its wedding dresses. BellasDress has chosen their ... for gift choices for the holiday season. , ... pick suitable wedding gowns here at discount prices. The ... experience at its website. , “All our ...
    (Date:12/25/2014)... 25, 2014 Recently, LunaDress.co.uk has updated its blog ... related accessories. Now, all of the models at LunaDress.co.uk come with ... groom lifts the wedding veil can turn out to be a ... A wedding veil can always bring surprise to a wedding. On ... how to choose veils for a big day . , ...
    (Date:12/25/2014)... 24, 2014 (HealthDay News) -- Among early stage breast ... than half of one percent will eventually develop leukemia ... reveals. The finding comes from a review of ... and 2007, and it suggests that the risk for ... experts had previously thought. "The frequency of bone ...
    (Date:12/25/2014)... SmileStix ” was featured on NewsWatch as part of its ... on the iOS, Android, and Windows markets. Andrew Tropeano, a ... review and shared with viewers how this is an application ... goes, “A picture says a thousand words.” It’s true. There ... image, because each picture holds a unique and special meaning. ...
    Breaking Medicine News(10 mins):Health News:BellasDress.com’s Christmas Sale: Trendy Wedding Dresses With Big Discounts 2Health News:LunaDress Provides Professional Tips On Shopping Wedding And Prom Dresses 2Health News:Breast Cancer Chemo Tied to Small But Significant Leukemia Risk 2Health News:Breast Cancer Chemo Tied to Small But Significant Leukemia Risk 3Health News:An Application to Create Custom Stickers was Featured on NewsWatch Television on December 19, 2014 2
    ... blood transfusion services for major hospitals throughout Washington ... provider of mobile productivity and management software, announced ... solution has been deployed by the Puget Sound ... access to wireless data and applications as they ...
    ... collection; simplifies UDS reportingTAMPA, Fla., March 24 ... integrated electronic health records and community health ... (FQHC) nationwide, Sage today announced that Family Health ... HealthLinc, formerly Hilltop Community Health Center, have selected ...
    ... Steps to Increase Participation in the School Breakfast ... L. Zahorchak today ate breakfast with 3rd graders ... breakfast programs and announce steps the department is ... who start the day with a healthy breakfast ...
    ... Veteran to Lead ItCOSTA MESA, Calif., March 24 ... it has hired Army Reserve officer Kirk Harrington, a ... as head of its newly-established warfighter division. Harrington is ... by the United States Department of State as a ...
    ... Cellegy Common Stock Expected to be Approximately 1: 9.929060BOYERTOWN, ... Board: CLGY) today announced that the stockholders of both ... merger of the two companies at stockholder meetings held ... subject to customary closing conditions, is expected to close ...
    ... March 24 Avidas(TM) Pharmaceuticals, a privately held, ... women,s health, today announced the launch of Scalacort(TM) ... in one patient convenience kit.Scalacort DK includes Scalacort ... in a clear fragrance-free base. Scalacort relieves itching ...
    Cached Medicine News:Health News:NetMotion Wireless Boosts Mobile Productivity for Puget Sound Blood Center 2Health News:NetMotion Wireless Boosts Mobile Productivity for Puget Sound Blood Center 3Health News:NetMotion Wireless Boosts Mobile Productivity for Puget Sound Blood Center 4Health News:Community Health Centers Select Sage Intergy CHC Community Health Management System 2Health News:Community Health Centers Select Sage Intergy CHC Community Health Management System 3Health News:Community Health Centers Select Sage Intergy CHC Community Health Management System 4Health News:Community Health Centers Select Sage Intergy CHC Community Health Management System 5Health News:Community Health Centers Select Sage Intergy CHC Community Health Management System 6Health News:PA Education Secretary Emphasizes Importance of Breakfast for Student Performance 2Health News:Oxygen Biotherapeutics, Inc. Establishes Warfighter Division 2Health News:Oxygen Biotherapeutics, Inc. Establishes Warfighter Division 3Health News:Cellegy and Adamis Stockholders Approve Merger Transaction and Related Proposals 2Health News:Cellegy and Adamis Stockholders Approve Merger Transaction and Related Proposals 3Health News:Avidas(TM) Pharmaceuticals Introduces Scalacort(TM) DK Which Offers Three Scalp Solutions in One Patient Convenience Kit 2Health News:Avidas(TM) Pharmaceuticals Introduces Scalacort(TM) DK Which Offers Three Scalp Solutions in One Patient Convenience Kit 3
    Toothed pituitary rongeur. Straight....
    Micro cup pituitary forceps, semi-malleable shafts....
    Teardrop dissector. 90, 5 mm....
    Papavero-caspar specula for trans-sphenoidal hypophysectomy....
    Medicine Products: